183 related articles for article (PubMed ID: 11393122)
1. Enhanced prostaglandin E2 secretion in sputum from asthmatic patients after zafirlukast therapy.
Tsai JJ; Su YC; Chan SC; Ho CK; Feng TC
J Formos Med Assoc; 2001 Apr; 100(4):241-3. PubMed ID: 11393122
[TBL] [Abstract][Full Text] [Related]
2. [The relationship between eosinophils, activated T lymphocyte, leukotreine and the exercise-induced asthma].
Guo Y; Sun T; Zhang H
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jun; 24(6):360-4. PubMed ID: 11802990
[TBL] [Abstract][Full Text] [Related]
3. Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics.
Basyigit I; Yildiz F; Kacar Ozkara S; Boyaci H; Ilgazli A; Ozkarakas O
Respirology; 2004 Nov; 9(4):514-20. PubMed ID: 15612964
[TBL] [Abstract][Full Text] [Related]
4. Leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects.
Perng DW; Huang HY; Lee YC; Perng RP
Chest; 2004 May; 125(5):1693-9. PubMed ID: 15136378
[TBL] [Abstract][Full Text] [Related]
5. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients.
Obase Y; Shimoda T; Tomari SY; Mitsuta K; Kawano T; Matsuse H; Kohno S
Chest; 2002 Jan; 121(1):143-50. PubMed ID: 11796443
[TBL] [Abstract][Full Text] [Related]
6. Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.
Laitinen A; Lindqvist A; Halme M; Altraja A; Laitinen LA
J Allergy Clin Immunol; 2005 Feb; 115(2):259-65. PubMed ID: 15696079
[TBL] [Abstract][Full Text] [Related]
7. Pranlukast, a cysteinyl leukotriene antagonist, reduces serum eosinophil cationic protein levels in patients with asthma.
Ishioka S; Hozawa S; Haruta Y; Hiyama K; Maeda A; Yamakido M
Hiroshima J Med Sci; 1999 Dec; 48(4):105-10. PubMed ID: 10804983
[TBL] [Abstract][Full Text] [Related]
8. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
Virchow JC; Prasse A; Naya I; Summerton L; Harris A
Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090
[TBL] [Abstract][Full Text] [Related]
9. Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study.
Huang CJ; Wang CH; Liu WT; Yang MC; Lin HC; Yu CT; Shiao CJ; Tan CC; Yang CK; Kuo HP
Chang Gung Med J; 2003 Aug; 26(8):554-60. PubMed ID: 14609035
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma.
Stelmach I; Jerzynska J; Kuna P
J Allergy Clin Immunol; 2002 Feb; 109(2):257-63. PubMed ID: 11842294
[TBL] [Abstract][Full Text] [Related]
11. [Sensitivity of sputum eosinophil cationic protein level for monitoring asthmatic patients with normal peak expiratory flow].
Nakazawa T; Kagami M; Matumura R; Kawashima T; Matuzuwa Y; Takada M
Arerugi; 1999 Oct; 48(10):1153-60. PubMed ID: 10554401
[TBL] [Abstract][Full Text] [Related]
12. Eosinophil count and eosinophil cationic protein concentration of induced sputum in the diagnosis and assessment of airway inflammation in bronchial asthma.
Park JW; Whang YW; Kim CW; Park YB; Hong CS
Allergy Asthma Proc; 1998; 19(2):61-7. PubMed ID: 9578913
[TBL] [Abstract][Full Text] [Related]
13. [Aspirin induced asthma, urinary leukotriene E4 and zafirlukast].
Orea Solano M; Flores Sandoval G; Machado C F; Romero H; Santos Argumedo L
Rev Alerg Mex; 2002; 49(2):52-6. PubMed ID: 12092526
[TBL] [Abstract][Full Text] [Related]
14. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.
Adkins JC; Brogden RN
Drugs; 1998 Jan; 55(1):121-44. PubMed ID: 9463793
[TBL] [Abstract][Full Text] [Related]
15. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients.
Cakmak G; Demir T; Gemicioglu B; Aydemir A; Serdaroglu E; Donma O
Tohoku J Exp Med; 2004 Dec; 204(4):249-56. PubMed ID: 15572850
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma.
Strauch E; Moske O; Thoma S; Storm Van's Gravesande K; Ihorst G; Brandis M; Kuehr J
Pediatr Res; 2003 Aug; 54(2):198-203. PubMed ID: 12736396
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of zafirlukast in the treatment of patients with bronchial asthma.
Tsai JJ; Chan SC; Ho CK; Su YC; Feng TC
J Microbiol Immunol Infect; 2001 Mar; 34(1):63-70. PubMed ID: 11321130
[TBL] [Abstract][Full Text] [Related]
18. Management of asthma with zafirlukast. Clinical experience and tolerability profile.
Spector SL
Drugs; 1996; 52 Suppl 6():36-46. PubMed ID: 8941502
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma].
Horiguchi T; Kondo R; Miyazaki J; Shiga M; Sugiyama M; Hirose M; Tachikawa S
Nihon Kokyuki Gakkai Zasshi; 2003 Oct; 41(10):696-703. PubMed ID: 14584388
[TBL] [Abstract][Full Text] [Related]
20. [The effect of salmeterol on the number of hypodense eosinophils, eosinophilic cationic protein levels ECP in serum, bronchial hyperresponsiveness and lung function test in patients with bronchial asthma].
Chazan R; Grubek-Jaworska H; Hermanowicz-Salomon J; Droszcz W
Pol Merkur Lekarski; 1997 Oct; 3(16):180-2. PubMed ID: 9461726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
